Argus II retinal prosthesis for retinitis pigmentosa in the Middle East: The 2015 Pan-American Association of Ophthalmology Gradle Lecture
J. Fernando Arévalo, Saba Al Rashaed, Tariq A. Alhamad, Eman Al Kahtani, Hassan Al-Dhibi, for the KKESH Collaborative Retina Study Group, Marco Mura, Eman Al Kahtani, Sawsan R. Nowilaty, Saba Al Rashaed, Hassan A. Al-Dhibi, Yahya Alzahrani, Igor Kozak, Sulaiman M. Alsulaiman, Abdulelah A. Al-Abdullah, Ahmad Albar, Yousef Al Dhafiri, Abdullah Al Qahtani, Khalid Al Rubaie, Saeed Al Shahrani, Maha Al Shehri, Badr Al Ahmadi, Abdulaziz Al Hadlaq, Majed Al Harbi, Abdulaziz Al Oreany, J. Fernando Arevalo
Abstract
BACKGROUND: To describe the outcomes of patients with retinitis pigmentosa (RP) who received the Argus II Retinal Prosthesis System. METHODS: This retrospective, interventional case series evaluated 10 consecutive patients who received the Argus II retinal implant and underwent visual function tests with the system on and system off. The main outcome measures were safety (the number, seriousness, and relatedness of adverse events), and visual function measured by computer-based objective tests, including square localization (SL) and direction of motion (DOM). Secondary measures included functional vision performance, including orientation and mobility (O&M) tasks. RESULTS: There were no intraoperative complications and all prostheses remained implanted at the end of follow up. The mean patient age was 41.3 years; mean duration of the implant in vivo was 2.1 years. One patient had a suture exposure over the coil suture tab and over the inferior case suture tab at 2 years postoperatively, which was managed successfully. One patient developed mild vitreous hemorrhage that resolved spontaneously. One patient developed high intraocular pressure postoperatively due to a tight scleral band (SB) that was managed successfully. Patients performed significantly better with the Argus II system on than off on all tasks. CONCLUSION: Patients who received the Argus II had a safety profile out to 4 years post-implantation that was markedly better than that observed in the pre-approval phase of the Argus II. In this population of RP patients, the Argus II retinal prosthesis provided useful visual function over several years that likely translates into improved quality of life. TRIAL REGISTRATION: clinicaltrials.gov identifier, NCT00407602.